We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMS Reevaluating Reimbursement Policies For EPO Drug Products
CMS Reevaluating Reimbursement Policies For EPO Drug Products
April 25, 2007
The Centers for Medicare & Medicaid Services (CMS) is reviewing its erythropoietin monitoring policy for end-stage renal disease patients undergoing dialysis following an FDA public health advisory announcing added warnings to erythropoiesis stimulating agents (ESAs), the CMS announced in February.